Is technetium-99m dimercaptosuccinic acid (DMSA) retained by the proximal renal tubular cells long enough to allow late-phase imaging?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Tc-99m DMSA is Retained Permanently by Proximal Renal Tubular Cells

Technetium-99m dimercaptosuccinic acid (DMSA) undergoes cortical tubular binding in the proximal renal tubules and is retained long enough to allow late-phase imaging, typically performed 1-4 hours post-injection, with acceptable images obtained even up to 24 hours in patients with advanced renal failure. 1, 2

Mechanism of Retention

The retention mechanism is well-established through recent research:

  • DMSA binds to metalloproteins in proximal tubular cells after being filtered through the glomeruli bound to α1-microglobulin (a ~27 kDa plasma protein) 3, 4

  • Uptake occurs via megalin/cubilin-mediated receptor endocytosis in the proximal tubules. Studies using megalin/cubilin-deficient knockout mice demonstrated that renal accumulation was reduced to only 11.4% of normal when these receptors were absent, confirming this is the primary uptake mechanism 3

  • Once internalized through this receptor-mediated endocytosis, DMSA remains bound within the cortical tubular cells with minimal excretion 4

Clinical Imaging Timeline

The retention characteristics make DMSA ideal for static cortical imaging:

  • Standard imaging window: 1-4 hours post-injection 2
  • Acceptable images can be obtained beginning 1-2 hours after administration 2
  • In patients with advanced renal failure, satisfactory images may be obtained by delaying imaging up to 24 hours 2
  • The product must be used between 10 minutes to 4 hours following reconstitution 2

Contrast with Other Renal Tracers

This retention pattern fundamentally differs from other renal imaging agents:

  • Tc-99m MAG3: Excreted via tubular secretion with >95% cleared within 3 hours in normal kidney function - designed for dynamic functional studies 1
  • Tc-99m DTPA: Excreted by glomerular filtration - also used for dynamic studies 1
  • DMSA's cortical binding makes it uniquely suited for static parenchymal imaging rather than functional drainage assessment 1

Important Clinical Caveats

Several conditions can impair DMSA uptake despite the retention mechanism:

  • Proximal tubular disorders (Dent disease, Lowe syndrome, renal tubular acidosis) show markedly decreased DMSA uptake even with normal creatinine clearance, because these conditions involve defective megalin/cubilin-mediated endocytosis 5, 6, 7

  • Acid-base imbalance can alter DMSA uptake independent of functional renal mass 7

  • Tubular proteinuria: DMSA uptake is inversely proportional to urine β2-microglobulin levels 5

  • Hematologic disorders/lymphohistiocytosis can cause altered biodistribution with hepatic and splenic uptake 4

Practical Application

The permanent cortical retention allows DMSA to serve as a marker of functional proximal tubule endocytic activity and cortical mass 3. This makes it the gold standard for:

  • Detecting renal cortical defects and scarring
  • Evaluating pyelonephritis
  • Assessing ectopic renal parenchyma
  • Quantifying differential renal function based on cortical uptake 8, 9

The retention is sufficiently stable that planar and SPECT images obtained 2-4 hours post-injection provide reliable assessment of cortical structure without concern for washout affecting image quality 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.